Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis

Launched by CHINESE ACADEMY OF MEDICAL SCIENCES, FUWAI HOSPITAL · Jan 6, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating whether taking a blood-thinning medication called rivaroxaban for 12 months, instead of the usual 6 months, can help patients with a condition called left ventricular thrombosis. This condition involves the formation of a blood clot in the heart's left ventricle, which can lead to serious problems like heart attacks or strokes. The goal is to see if the longer treatment duration can lower the risk of these major health events and reduce the chances of the clot coming back, while also checking for any significant bleeding risks.

To participate in this trial, you must be at least 18 years old and have a confirmed diagnosis of left ventricular thrombus through heart imaging tests. Unfortunately, some people may not be eligible, such as those who have allergies to blood thinners or certain other health conditions. If you join the study, you’ll need to attend 12 follow-up visits over the year to monitor your health and ensure the treatment is working well. This is an important study that could help improve care for patients with this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ①Patients who have been clearly diagnosed with left ventricular thrombus by inpatient or outpatient cardiac ultrasound (including general ultrasound and acoustic imaging).
• • ②Age \>= 18 years old
• Exclusion Criteria:
• • Patients do not agree to participate in the study or have poor compliance in the past
• • Contraindication to anticoagulation or allergy to anticoagulants ③Have received oral anticoagulation after diagnosis of left ventricular thrombus.
• • Have undergone or are planning to undergo surgical procedures including left ventricular appendage thrombectomy, heart transplantation, ventricular wall tumor collapse, or valve replacement.
• • Presence of other long-term indications for anticoagulation, such as mechanical valve implantation, atrial fibrillation, etc.
• • Requirement for treatment with Tegretol and inability to change to clopidogrel bisulfate ⑦Presence of known malignant tumors, severe hepatic dysfunction (Child-Pugh classification B or less), severe renal dysfunction (creatinine clearance \<30ml/min), anemia (Hb \<100g/L), coagulation disorders and other underlying diseases, or life expectancy \<3 years ⑧ Female patients are pregnant or breastfeeding ⑨ Patients with antiphospholipid syndrome